Cimeio Therapeutics

Cimeio is an applied gene-editing and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs™ (SCIP), which has the potential to transform haematopoietic stem cell (HSC) transplantation. The company's technology platform is based upon the design and expression of modified variants of naturally occurring cell surface proteins in HSCs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, haematologic malignancies, and severe autoimmune disorders.